Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
atai Life Sciences (Nasdaq: ATAI) plans to host a conference call on August 16, 2021, at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2021, and provide a business update.
The conference call can be accessed at 877-407-3982 in the U.S. and +1 (201) 493-6780 internationally, using conference ID: 13721888. A live and archived webcast will be available on the company's website.
atai Life Sciences N.V. (Nasdaq: ATAI) will participate in the virtual 41st Annual Canaccord Genuity Growth Conference from August 10-12, 2021. The company will conduct a fireside chat on August 10 at 2:30 p.m. ET. Interested parties can access the webcast here.
atai Life Sciences N.V. (Nasdaq: ATAI) announced its participation in the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. The company, focused on developing innovative therapies for mental health disorders, will present at 10:50 AM ET. Interested parties can access the presentation via a webcast link provided in the announcement. A replay will be available on atai's website. Founded in 2018, atai aims to transform mental health treatment through psychedelic and non-psychedelic compounds.
atai Life Sciences has priced its upsized initial public offering (IPO) at $15.00 per share, totaling 15,000,000 common shares and expected to raise $225.0 million. The offering is set to close on June 22, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,250,000 shares at the offering price. Trading on the Nasdaq Global Market under the symbol ATAI begins on June 18, 2021. This IPO is crucial for atai's future endeavors in mental health treatment innovations.
atai Life Sciences announced an initial public offering (IPO) of 14,286,000 common shares, priced between $13.00 and $15.00 each. The underwriters have a 30-day option to purchase an additional 2,142,900 shares. The offering aims to enhance atai's capabilities in mental health treatments using innovative therapies. The shares are set to list on the Nasdaq under the ticker symbol ATAI, with Credit Suisse, Citigroup, and others acting as book-running managers. A registration statement has been filed but is not yet effective.